FDA Issues Letter Regarding Lebrikizumab Review for AD FDA Issues Letter Regarding Lebrikizumab Review for AD

The FDA has issued a complete response letter regarding lebrikizumab, an investigational biologic for the treatment of adult and adolescent patients with moderate to severe atopic dermatitis.MDedge News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Dermatology News Source Type: news